PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March... Read More

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases Invented by VEGF pioneer Dr. Napoleone Ferrara, TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept, and... Read More

Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023... Read More

WALTHAM, Mass. / Nov 16, 2023 / Business Wire / AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET. A live webcast and archived replay of the presentation... Read More

Posoleucel, a highly innovative off-the-shelf, multi-virus-specific investigational T cell therapy, continues to advance in three distinct, Phase 3, first-to-market indications in immunocompromised patients Enrollment in posoleucel pivotal Phase 3 multi-virus prevention, virus-associated hemorrhagic cystitis and adenovirus studies all progressing with topline data for all three studies anticipated in the second half of 2024... Read More

WALTHAM, Mass. / Aug 28, 2023 / Business Wire / AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference Fireside Chat: Monday, September 11, 2023 at 4:55 pm ET H.C. Wainwright 25 th Annual Global... Read More

Company's three Phase 3 global registrational trials for its allogeneic, off-the-shelf, virus-specific T cell therapy, posoleucel, in three distinct, first-to-market indications in allo-HCT patients continue to enroll, with data anticipated in second half of 2024 Positive data from the Phase 2 trial of posoleucel for treatment of BK viremia in kidney transplant recipients presented orally at late-breaking session at the... Read More

WALTHAM, Mass. / Jun 21, 2023 / Business Wire / AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.75 per share. The gross proceeds to AlloVir from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are... Read More

CAMBRIDGE, Mass. / Jun 21, 2023 / Business Wire / AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that it has commenced a proposed underwritten public offering of $75.0 million of shares of its common stock. AlloVir also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of its common stock offered in the public... Read More

Posoleucel demonstrated clinically meaningful reductions in BK viral load as compared to placebo with the greatest antiviral activity seen among patients with higher viral loads and those who received more frequent posoleucel dosing At Week 24, the percentage of patients with a ≥1-log viral load reduction in the biweekly dosing group was 50% (10/20) vs. 28% (5/18) in the monthly dosing group and 14% (2/14) in the placebo... Read More

Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities WALTHAM, Mass. / May 16, 2023 / Business Wire / AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company’s Chief Commercial Officer, effective... Read More

Company’s three posoleucel Phase 3 global registrational trials for three distinct, first-to-market indications continue to enroll with data readouts on track for 2024 Positive results from a randomized, double-blind, placebo-controlled Phase 2 study of posoleucel in kidney transplant recipients with BK viremia will be presented at the American Transplant Congress 2023 later this quarter WALTHAM, Mass. / May 04, 2023 /... Read More

WALTHAM, Mass. / May 01, 2023 / Business Wire / AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, announced today that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas, NV on Tuesday, May 9, 2023, at 8:40 a.m. PDT. A live webcast and archived replay of the presentation will be available... Read More

Day 400 non-relapse mortality was 0% Previously reported data from the 14-week primary endpoint showed low rates of clinically significant viral infections and diseases in this high-risk patient population despite the expected high rates of viral reactivation Global Phase 3 pivotal posoleucel trials continue to progress with robust patient enrollment in the US, Europe and Asia with data readouts on track for 2024 WALTHAM,... Read More

WALTHAM, Mass. / Feb 23, 2023 / Business Wire / AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Derek Adams, Ph.D., to its Board of Directors, effective March 1, 2023. Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development. “I am thrilled that Derek is joining AlloVir’s... Read More

WALTHAM, Mass. / Feb 15, 2023 / Business Wire / AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported full-year 2022 financial results for the period ended December 31, 2022. The company also highlighted its progress and provided the outlook for 2023 and into 2024 across its allogeneic, off-the-shelf, virus-specific T cell (VST) programs, including its lead... Read More

Positive final posoleucel Phase 2 clinical data presented at ASH 2022 underscore potential as multi-virus prevention therapy and support ongoing global Phase 3 registration trial Completion of enrollment of all three posoleucel Phase 3 registrational trials anticipated by the end of 2023 and data readouts in 2024 Topline results of posoleucel Phase 2 BKV treatment study in kidney transplant patients expected in 1Q 2023... Read More

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST. A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at... Read More

23 of 26 (88%) patients remained free of clinically significant infections caused by any of six common viruses that posoleucel targets through the Week 14 primary endpoint 3 of 26 (12%) patients had clinically significant infections despite 22 of 26 (85%) patients reactivating one or more of six potentially devastating viruses Biomarker data support the clinical results by demonstrating expansion of functional virus-specific... Read More